ClearSight Therapeutics Receives NIH SBIR Phase I Award for Conjunctivitis and EKC Research
Sep 22, 2026
DALLAS - Sept. 22, 2026 - PRLog -- ClearSight Therapeutics, Inc. Receives NIH SBIR Phase I Award for Research in Acute Infectious Conjunctivitis and EKC
Competitive federal award provides external scientific validation of the proposed research program and funds a disciplined path to new evidence
DALLAS, September 22nd, 2026 - ClearSight Therapeutics, Inc., a Dallas-based eye-care company, today announced that it has received a $306,852 Small Business Innovation Research Phase I award from the National Eye Institute, part of the National Institutes of Health. The competitive award marks a major scientific milestone for ClearSight and supports a one-year investigational research program involving a preservative-free ophthalmic formulation in acute infectious conjunctivitis and epidemic keratoconjunctivitis.
The project, award number R43EY039140, runs from September 15, 2026 through August 31, 2027. ClearSight Chief Scientific Officer Nuria Jimenez, PhD, PMP, will serve as principal investigator. The Notice of Award identifies the project as research and development and states that it does not support an NIH-defined clinical trial.
Why this award matters
NIH funding decisions follow rigorous peer review of scientific and technical merit and a second-level assessment of mission relevance. Reviewers consider the importance of the proposed research, the rigor and feasibility of the approach, and whether the investigators and organization have the expertise and resources to carry out the work. For ClearSight, the award provides meaningful external validation of the proposed scientific program and creates an accountable path for turning a promising research premise into credible evidence. It does not predetermine the results; it makes the disciplined work to generate those results possible.
"This award is a defining milestone for ClearSight. Following competitive review of the scientific and technical merit of our proposed work, NIH support gives us both meaningful external validation and non-dilutive capital to build the evidence base with rigor. It is a powerful vote of confidence in the importance of the question, the strength of the research plan, and our team's ability to execute."
Patrick Smale, Co-founder and Chief Executive Officer
"The questions at the center of this program matter to patients, clinicians, and the broader eye-care community. NIH support gives us the opportunity to investigate them with the rigor they deserve, generate credible data, and let the evidence guide what comes next. I am proud to lead this work alongside our team and collaborators."
Nuria Jimenez, PhD, PMP, Chief Scientific Officer and Principal Investigator
"I am excited and grateful for this initial support from the National Eye Institute, which represents an important step in advancing our innovation toward clinical development. This funding will enable us to generate the rigorous data needed to further validate the technology and its potential to address important unmet needs in topical ocular therapy. As a co-inventor and drug developer, I am particularly encouraged by the opportunity to translate this innovation into a product where patient safety, efficacy, and meaningful clinical benefit remain our highest priorities."
Suchismita Acharya, PhD, Co-Founder, Co-Inventor and Board Member
The SBIR program supports research and development by eligible small businesses. Beyond providing non-dilutive capital, the award gives ClearSight a structured milestone period through August 2027 and an accountable framework for translating a scientific premise into data. The work will proceed under a defined research plan, milestones, and federal reporting obligations.
Important regulatory context
ClearSight's NIH-funded research program will study preservative-free ophthalmic formulation in acute infectious conjunctivitis and EKC. This investigational research is separate from the labeled uses of any OTC lubricant eye drop marketed under M018 and does not establish safety, efficacy, or regulatory approval for treating either condition.
About ClearSight Therapeutics
ClearSight Therapeutics is a Dallas-based eye-care company founded in 2023 by industry veterans to develop accessible solutions for common ocular conditions. The company maintains distinct commercial and research programs, including OTC lubricant development under applicable monograph labeling and separately described investigational research. Learn more at clearsighttx.com.
NIH funding acknowledgment
Research reported in this release is supported by the National Eye Institute of the National Institutes of Health under Award Number R43EY039140. A total of $306,852, or 100% of the project, is financed with federal funds. A total of $0, or 0%, is financed with non-governmental funds. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Media contact
Patrick Smale
Co-founder & CEO
ClearSight Therapeutics
[email protected]
972-983-7761
Photos: (Click photo to enlarge)
Source: ClearSight Therapeutics, Inc.
Read Full Story - ClearSight Therapeutics Receives NIH SBIR Phase I Award for Conjunctivitis and EKC Research | More news from this source
Press release distribution by PRLog
Trough of TD to bring rains in Visayas, Mindanao — Pagasa
MANILA, Philippines — The trough of the tropical depression (TD) will continue to bring rains over Visayas and Mindanao on Wednesday, Sept. 23, the state weather bureau said. Philippine Atmospheric, Geophysical and Astronomical Services Administration (Pagasa) weather specialist Benison Estareja said during its 5 p.m. weather advisory that the extension of the TD outside of
Student wounded in South Cotabato’s school attack recovering after surgery
KORONADAL CITY — Five days after she was critically wounded in the Banga National High School shooting in South Cotabato, a Grade 9 female student who suffered a gunshot wound in the head is showing signs of recovery. This development comes after the victim underwent surgery at the Cotabato Regional and Medical Center in Cotabato
Cagayan de Oro multi-stakeholder dialogue tackles Pax Silica
CAGAYAN DE ORO CITY — To address growing concerns over Pax Silica, the Archdiocese of Cagayan de Oro-Commission on Social Apostolate and the Samdhana Institute convened a multi-stakeholder dialogue on Tuesday at the San Agustin Metropolitan Cathedral here. The whole-day event, themed “Opportunities, Risks and Responsibilities for People, Planet and Peace,” gathered members of the
PH, Australia advance $45M grant to project-selection stage
MANILA, Philippines — The Philippine and Australian governments have started identifying projects, including those in renewable energy and the digital economy, to fund with a A$45-million grant designed to boost the country’s economic growth over the next five years. In a press briefing, Australian Assistant Minister for Foreign Affairs and Trade Matt Thistlethwaite said the
Trump praises Takaichi for doing ‘tremendous job’ ahead of Xi’s visit to US
US President Donald Trump praised his strong relationship with Japanese Prime Minister Sanae Takaichi in New York on Tuesday, days before he is due to meet with Chinese President Xi Jinping. The talks, held on the sidelines of the United Nations General Assembly, came at a time when relations between Beijing and Tokyo show no signs of thawing. Both leaders hailed their good working relationship, with Takaichi saying the two countries looked forward to deepening ties. Trump lavished praise on the...
Senate measure removing system loss charges reaches plenary
MANILA, Philippines — The bill seeking to remove system loss costs incurred by electric providers to consumers reached the Senate floor on Tuesday. Sen. Erwin Tulfo stood before the plenary to sponsor Senate Bill No. 2486, otherwise known as the “Systems Loss Charge Removal Act.” READ: Sona promise: Lower power bills as VAT on system
Gov’t eyes P4.05B for 5 Metro Manila rain catchment facilities
MANILA, Philippines — The Marcos administration needs more than P4 billion to construct five of the 39 proposed rainwater impounding facilities in Metro Manila to address the perennial flooding problem in Metro Manila. The five projects have a combined indicative cost of about P4.05 billion, subject to the applicable government review, approval, budgeting and procurement processes,
Dy to QC barangay execs: Keep up ‘honest, responsive’ service
MANILA, Philippines — Since the success of Quezon City, Metro Manila’s largest local government unit, relies on strong barangays, its officials should keep strengthening their communities through “honest, responsive, and compassionate leadership.” House Speaker Faustino “Bojie” stressed that message in his address on Monday evening during the 31st Quezon City Barangay Day Celebration at the Grand
PH bond market growth slows despite lower yields
MANILA, Philippines — The Philippine bond market grew more slowly in the second quarter, even as local yields declined and bucked the Bangko Sentral ng Pilipinas’ (BSP) ongoing rate-hiking cycle, the Asian Development Bank (ADB) said. In its latest “Asia Bond Monitor” report, the Manila-based multilateral lender said outstanding local currency bonds, excluding debt securities with
CICC gives Reddit, Discord 24 hours to establish PH offices
The Cybercrime Investigation and Coordinating Center (CICC) has given Reddit and Discord 24 hours to establish offices or designate local representatives in the Philippines, as the government moves to strengthen coordination with digital platforms following three school shooting incidents in recent months.
DepEd thanks House for approving P975.96-B budget for 2027
MANILA, Philippines — The Department of Education (DepEd) thanked the House of Representatives for approving its proposed P975.96 billion budget for 2027, which accounts for 13.55 percent of the P7.2-trillion national budget. “We deeply appreciate the House of Representatives’ strong commitment to education and the leadership of President Ferdinand R. Marcos Jr. in advancing the
Cayetano accuses PRA of ‘selective justice’ on reclamation rules
MANILA, Philippines — Sen. Alan Peter Cayetano accused the Philippine Reclamation Authority (PRA) of “selective justice” in enforcing rules on reclamation projects. He questioned why the PRA issued a cease-and-desist order against a project in Taguig but not the Laguna Lake Shore Road Network (LLRN). “Ongoing now is a massive [Department of Public Works and
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.